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eople with CKD have an elevated risk of developing
chronic HCV infection.1–4 Chronic HCV infection in
the setting of CKD can accelerate decline of kidney
function, increase the risk of kidney failure,5–8 and
increase the likelihood of mortality in dialysis pa-
tients.9 Fortunately, effective treatment for HCV de-
creases the incidence of CKD8 and improves kidney and
cardiovascular outcomes in patients with diabetes.10 In
2008, KDIGO published the first comprehensive clinical
practice guideline on the diagnosis, prevention, and
treatment of HCV in CKD.11 At that time, treatment
options for HCV in CKD G4 and G5 were limited to
interferon with or without ribavirin. Because both
interferon and ribavirin are eliminated by the kidney,
dose reductions are necessary in patients with
advanced CKD. Additionally, interferon and ribavirin
have poor efficacy and tolerability, especially in pa-
tients undergoing dialysis.9
In the past decade, oral antiviral therapies that
directly target HCV replication have become available,
with high efficacy rates and good tolerability profiles.
Several regimens without interferon and ribavirin have
been approved for use in patients with HCV infection
and an estimated glomerular filtration rate <30 ml/min
per 1.73 m2, including those on dialysis.12,13 Diagnostic
methods for determining severity of liver disease have
also expanded, and the extent of liver fibrosis can now
be assessed using non-invasive measures such as tran-
sient elastography.12,13 Given the advances in di-
agnostics and therapeutics, a comprehensive update of
the KDIGO HCV in CKD guideline was undertaken and
published in 2018.14
Multiple factors influence the extent of guideline
incorporation into clinical practice, such as government
health policies, drug availability, reimbursement pol-
icies, local economic determinants, and regulatory de-
cisions. KDIGO, in collaboration with the Chinese
University of Hong Kong and the Prince of Wales
Hospital, Hong Kong, organized the first HCV Guide-
line Implementation Summit in May 2019 in Hong
Kong. The goal of the summit was to understand
practice patterns for preventing and managing HCV in
CKD in 8 Southeast Asian countries or regions with
comparable high or middle economic ranking by the
World Bank.15 Nephrologists, hepatologists, and nurse
consultants from mainland China, Hong Kong, Japan,
Malaysia, Singapore, South Korea, Taiwan, and
Thailand attended the meeting and contributed to
discussion. Meeting participants shared information
related to the availability and reimbursement of direct-
acting antiviral (DAA) therapies in each country or
region, the current uptake and implementation of the
KDIGO HCV in CKD guideline, as well as specific bar-
riers to implementation. Finally, strategies aimed at
MEETING REPORT1130overcoming these barriers and improving quality of
care were developed.
HCV INCIDENCE AND PREVALENCE IN ASIA
Globally, approximately 70 million people have chronic
infection with HCV.16 Prevalence rates vary throughout
the world, as well as throughout East and Southeast
Asia.17 Gower et al. reported in 2014 an estimated
prevalence of HCV RNA positivity of 3.3% in Taiwan,
1.7% in Thailand, 1.1% in Japan and Malaysia, 0.8% in
mainland China, 0.4% in the Republic of Korea, and
0.3%–0.5% in Hong Kong.17 HCV genotype distribu-
tion also varies throughout Asia. For example, HCV
genotype 3 infection is more prevalent in Malaysia
(59%) and Thailand (44%) compared with other regions
in Asia and with the global population (22%).17
In patients with kidney failure, dialysis modality is
an independent predictor of the likelihood of acquiring
HCV infection, with hemodialysis (HD) being associ-
ated with a higher risk of HCV infection than perito-
neal dialysis.18 Internationally, HCV seroprevalence
and seroconversion rates among dialysis patients vary
widely, suggesting a need for consistent, rigorous local
infection control measures. We have updated HCV
prevalence in the 8 Southeast Asian countries and re-
gions participating in the summit (Figure 1). Overall,
the HCV prevalence in the HD population as deter-
mined by anti-HCV antibody testing ranges from 0.9%
in Hong Kong to 13% in Taiwan. The HCV prevalence
in peritoneal dialysis patients is lower than that in their
HD counterparts, ranging from 0.8% in Hong Kong
and China to 5% in Taiwan (Figure 1). Since the HCV
prevalence data were largely based on anti-HCV anti-
body positivity rather than HCV RNA positivity, some
of the anti–HCV-positive patients may in fact have
been cured of HCV after DAA therapy despite
harboring anti-HCV antibodies (e.g., Taiwan).
CURRENT UPTAKE OF HCV IN CKD GUIDELINE
In a pre-meeting survey, approximately 75% of 20
respondents indicated that their country or region has
local guidelines on treating HCV in patients with CKD
or on dialysis. Fewer than 20% indicated that there are
critical differences between the local guidelines and the
KDIGO HCV in CKD guideline. Indeed, participants
indicated that all regions follow most of the guidance
put forth by the KDIGO HCV in CKD guideline, as
described below.
Detection and Evaluation of HCV in CKD
Method of Detection
Consistent with the KDIGO HCV in CKD guideline, all
participating regions reported screening for HCV using
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Figure 1. Prevalence of hepatitis C virus (HCV) in hemodialysis (HD)
and peritoneal dialysis (PD) in Southeast Asian countries and re-
gions. China data (2019) are based on estimates of data from 6
provinces and 7 major cities; Hong Kong data (2019) are based on
Hong Kong Renal Registry; Japan data (2018) are based on the
Japanese Society for Dialysis Therapy Registry; Malaysia data (2017)
are based on the Malaysian Dialysis and Transplant Registry;
Singapore data (2018) are based on the Renal Registry of Singapore;
South Korea data (2018) are based on the Korean Society of
Nephrology Registry; and Taiwan data (2017) are based on the
Taiwan Renal Registry. Thailand data (2019) are based on the Renal
Registry of Thailand. HCV prevalence data were largely based on
anti-HCV antibody positivity rather than HCV RNA positivity. There-
fore, some of the anti–HCV-positive patients may in fact have been
cured of HCV after direct-acting antiviral therapy despite harboring
anti-HCV antibodies (e.g., Taiwan).
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tive. Because of its relatively low cost, this anti-HCV
assay will likely remain the initial screening test for
patients on HD in most regions. In Malaysia, where
polymerase chain reaction analysis is available in only a
few central laboratories, the HCV core antigen test is
being considered as an alternative to nucleic acid
testing because HCV core antigen testing costs less and
allows confirmatory evaluation to be decentralized.
Given that HCV core antigen has a detection threshold
of at least 3000 IU/ml, and most patients with HCV
have high levels of viremia, good concordance between
HCV core antigen and polymerase chain reaction has
been demonstrated.19–21 Currently, HCV core antigen is
not yet available in Hong Kong and is relatively
expensive in Singapore and mainland China.
Frequency of Testing
For HD patients, all of the participating regions except
2 perform HCV screening tests at 6-month intervals,Kidney International Reports (2020) 5, 1129–1138consistent with the KDIGO HCV in CKD guideline. In
Taiwan, HCV screening of HD patients is done every 12
months because of reimbursement policies. In
Singapore, HD patients are screened every 3 months, a
practice initiated in response to an outbreak of 25 cases
of acute HCV infection in the renal ward at Singapore
General Hospital in 2015.22
Nearly all participating regions reported that nucleic
acid testing is performed annually for patients who
either are on HD and anti–HCV-positive, have sponta-
neously cleared HCV, or have achieved sustained
virologic response after treatment. An exception is
Malaysia, where nucleic acid testing is not repeated
except in the context of HCV treatment.
Treatment of HCV Infection in Patients With CKD
Choice of Regimen
The KDIGO HCV in CKD guideline recommended that
all CKD patients with HCV be considered for treatment
with an interferon-free regimen. Recommended first-
line treatment for patients with CKD G4 or G5
(including HD patients) is either glecaprevir/pibren-
tasvir for all HCV genotypes or grazoprevir/elbasvir for
HCV genotypes 1 and 4 (Figure 2).14,23
At the time of HCV in CKD KDIGO guideline pub-
lication, and during the HCV in CKD Asia summit,
sofosbuvir-based regimens were not recommended for
CKD G4 or G5 (estimated glomerular filtration rate < 30
ml/min per 1.73 m2).12,13 However, in November 2019,
the US Food and Drug Administration extended the
label of sofosbuvir to include CKD G4 and G5 patients
and those on dialysis. Although sofosbuvir-based reg-
imens may provide a treatment option in countries
where glecaprevir/pibrentasvir and/or grazoprevir/
elbasvir are not available, this label extension is as yet
limited to the US and is based on pharmacokinetic data
and several case series rather than on randomized
controlled trial data.
Although daclatasvir plus asunaprevir was listed as
a treatment option in HCV genotype 1a and 1b patients
with CKD G4 or G5,14,24–28 evidence from Japan sug-
gests that daclatasvir/asunaprevir has suboptimal effi-
cacy against genotype 1a.29,30 Meeting participants felt
that all patients who have chronic HCV infection
should be treated, regardless of the extent of liver
fibrosis, although in some regions, treatment is
currently prioritized based on the extent of liver
fibrosis. Availability and accessibility of originator and
generic DAA regimens vary greatly among the regions
represented (Table 1). Lack of availability and high
costs or copays were identified as major barriers to
treatment. In some regions, a major barrier for CKD
patients is that consultation with a hepatologist is
necessary for DAA therapy. Additionally, technology1131
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CKD G5 PD n/a (reasonable to follow proposed regimens for HD)
1a Sofosbuvir with ledipasvir,
daclatasvir or simeprevir  
D2nirivabir/rivubsofoSB1
Glecaprevir/pibrentasvir c 1C
1b Sofosbuvir with ledipasvir,
daclatasvir or simeprevir 
1B
Glecaprevir/pibrentasvir c 1C
2, 3, 5, 6 Glecaprevir/pibrentasvir c 1D Sofosbuvir/daclatasvir/ribavirin d 2D
4 Sofosbuvir with ledipasvir,








(GFR ≥ 30 ml/min per
1.73 m2)
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as PrOD or 3D regimen)
with ribavirin  
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as ProD or 3D regimen)
Figure 2. Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and kidney
transplant recipients (KTRs), by hepatitis C virus (HCV) genotype.a Duration of therapy for all these regimens is usually 12 weeks, but readers
should consult the American Association for the Study of Liver Diseases (AASLD) or the European Association for the Study of the Liver
guidelines for the latest information. Use of daclatasvir/asunaprevir is generally more appropriate for patients with genotype 1b, as it is less
efficacious in HCV genotype 1a. The US Food and Drug Administration has recently indicated that no dose adjustments are required for
sofosbuvir-based regimens in CKD patients, including those on dialysis based on pharmacokinetic data and several case series rather than on
randomized controlled trial data. These regimens may be considered pending their availability in various jurisdictions. However, readers are
encouraged to consult https://www.hep-druginteractions.org/ for drug–drug interactions, particularly with immunosuppressants (e.g., cyclo-
sporine, sirolimus, and tacrolimus). aIt was recommended that CKD patients with glomerular filtration rates (GFRs) $ 30 ml/min per 1.73 m2 (CKD
G1T–G3bT) be treated with any licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30
ml/min per 1.73 m2 (CKD G4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin in-
hibitors. cBased on Reau et al.23 dAs suggested in AASLD guidelines (https://www.hcvguidelines.org), HCV protease inhibitors that end in
“previr,” such as glecaprevir or grazoprevir, should not be used in patients with decompensated cirrhosis.12,13 HD, hemodialysis; n/a, no data/
evidence available; PD, peritoneal dialysis.
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elastography, may be available only to hepatologists.
Multiple regions, including Taiwan and Korea, cited
patients’ lack of awareness of their HCV status or of
treatment efficacy as a major barrier to treatment.
Drug–Drug Interactions
In line with the KDIGO HCV in CKD guideline, par-
ticipants commonly referred to the Hepatitis Drug In-
teractions website from the University of Liverpool
(http://www.hep-druginteractions.org) as their pri-
mary reference tool for minimizing drug–drug
interactions.
Hepatitis B Screening
Most participants indicated that they screen for hepa-
titis B surface antigen and anti-hepatitis B core1132antibody (anti-HBc) before starting DAAs. In HCV
patients positive for the antigen, the benefits of HCV
treatment versus the risk of hepatitis B virus (HBV)
reactivation must be considered. Patients with HBV/
HCV coinfections who are not undergoing treatment
for hepatitis B or who are positive for anti-hepatitis B
core antibody must have alanine aminotransferase
levels monitored during DAA therapy.
Preventing HCV Transmission in HD Units
Participants felt that physicians are ultimately
responsible for ensuring infection control measures and
for quality assurance practices in their units. Nursing
staff should provide input in creating guidelines for
quality assurance and be involved in training staff
members on quality assurance practices. In manyKidney International Reports (2020) 5, 1129–1138
Table 1. DAA treatments for chronic hepatitis C in Asian regions
Country/region Available DAAs Payment policies Fibrosis status restrictions CKD restrictions Specialist restrictions
China mainland All major originator drugs are
available.





No restrictions No restrictions For CKD G1–G3, need to refer to
hepatologist. For CKD G4 or above,
nephrologist can initiate treatment.
Hong Kong Licensed generics are not available. Covered by the Hospital Authority if
reimbursement criteria are met
CKD patients with fibrosis stage F2
would receive DAA.
Treatment coverage to all dialysis
patients, irrespective of waitlist status
for transplants, can receive DAA.
Need referral to hepatologist
Korea All originator drugs are available.
Licensed generics are not available.
Covered by national insurance,
although copays can be high
Protease inhibitors are prohibited in
decompensated cirrhosis and
dasabuvir, GLE, GZR, and voxilaprevir
are to be avoided in moderate to severe
liver failure. DAA treatment is currently
not reimbursed in untreated HCC or
relapsed patients. (Reimbursement
criteria updated periodically by Health
Insurance Review & Assessment
Service [HIRA])
Recommend avoiding sofosbuvir in
patients with severe kidney impairment
(eGFR <30 ml/min per 1.73 m2)
No restrictions but usually in
consultation with hepatologist
Japan Licensed generics are not available. Covered by national insurance,
although patients also pay out-of-
pocket










No restrictions but usually in
consultation with hepatologist
Malaysia Generic sofosbuvir and daclatasvir
are currently available in public
hospitals.
In private practice, some originators
are available (sofosbuvir, ledipasvir/
sofosbuvir, sofosbuvir/velpatasvir).
Generic DAAs covered by Ministry
of Health; patients must pay for
originators.
No restriction except that protease
inhibitors GLE and GZR cannot be used
in decompensated cirrhosis
If eGFR <30 ml/min per 1.73 m2,
formerly GZR/EBR and 3D could be
used for priority for transplant
candidates. However, these are not
available in the Malaysian market
anymore. GLE/PIB are likely to be
approved in 2020 but may be restricted
in use because of cost.
Primary care is able to treat
uncomplicated hepatitis C with
generic SOF and daclatasvir. For
complicated cases such as patients
with CKD, due to the cost of GLE/
PIB, hepatologist/gastroenterologist
consultation is required.
Singapore All originator drugs are available.
Licensed generics are not available.
Copays can limit patient access. No restrictions No restrictions No need for hepatologist referral
Taiwan All originator drugs are available.
Licensed generics are not available.
Covered by national health
insurance
No restrictions No restrictions Need referral to hepatologist
Thailand Generic drugs are available but may
be restricted in some circumstances.
Government coverage mostly No restrictions Only sofosbuvir-based regimens
available.
Treatment decisions mostly by
hepatologists; nephrologists cannot
prescribe DAAs
3D, ombitasvir/paritaprevir/ritonavir þ dasabuvir; CKD, chronic kidney disease; DAA, direct-acting antiviral; eGFR, estimated glomerular filtration rate; GLE/PIB, glecaprevir/pibrentasvir; GZR/EBR, grazoprevir/elbasvir; HCC, hepatocellular carcinoma;


























































































MEETING REPORT PK-T Li et al.: KDIGO HCV Guideline Implementation Asia Summitcenters in Hong Kong, patients are encouraged to
remind staff of infection control practices, including
hand hygiene.
Staff Education
All participants reported training of new staff mem-
bers, and the majority reported repeat training between
once and twice a year. Thailand, Taiwan, Malaysia, and
Korea report yearly training; Japan and mainland China
report training twice a year. In Hong Kong, most
dialysis facilities refer to “Clinical Practice Guidelines
for the Provision of Renal Service in Hong Kong”
published by the Hong Kong College of Physicians,
Central Renal Committee of Hospital Authority and
Hong Kong Society of Nephrology.31 This guideline
was recently updated following its first publication
in 1999.
All HD staff should attend infection control
refresher training at least once every 24 months. In
mainland China, routine nurse training programs are
provided twice per year, and nurses from satellite units
meet in central cities for lectures on infection control
measures. Taiwan has yearly continuing medical edu-
cation programs, and the renal society offers accredi-
tation (funded by insurance). In Korea, infection
control guidelines from the Korean Society of
Nephrology are implemented. HD quality practices,
including screening for anti-HCV antibodies, are
assessed annually by a national health insurance re-
view. In Singapore, all new staff members review
written protocols for infection control and subse-
quently are tested on their knowledge of the material.
Clinical practice improvement projects such as Rapid
Improvement Events (RIEs) are used to identify short-
falls and implement continuous quality improvement
initiatives. In cases of lapses, corrective measures
are taken. In Malaysia, infection control measures are
covered in national HD quality standards, and ne-
phrologists and senior paramedics lead annual refresher
courses on infection control in dialysis. In Thailand,
staff must be accredited (i.e., have received training
for 6 months, plus have 4 years of experience in HD
centers, with a minimum of 1000 HD sessions to qualify
for a state license examination) prior to working in
dialysis units, with infection control a part of the
curriculum. Refresher courses are required annually.
Other Organizational Aspects
Participants reported that auditing measures are in
place in most dialysis units in their regions. All regions
report having reasonable infrastructure (e.g., adequate
space for dialysis stations) and staffing ratios (1:1 for
intensive care, 1:3 for HD units in Hong Kong). Taiwan
will soon embark on a microelimination program in
which all HCV patients in the same unit are treated at1134the same time, to prevent transmission32; an early
treatment program for new HCV patients is underway
there.
Care Bundles for Preventing Nosocomial Infections
Care bundles for preventing blood-borne virus trans-
mission should incorporate careful hygienic pre-
cautions (especially handwashing and changing gloves
between patients), periodic testing of patients, and
cleaning of dialysis machines (including their surface)
and blood- or body-fluid contaminated environmental
areas with 1% sodium hypochlorite solutions or
another disinfecting agent as recommended by the
manufacturer of the HD machines. For patients with
hepatitis B, isolation is practiced, and dialyzers are not
reused. A clustered randomized controlled trial could
be used to evaluate the effectiveness of care bundles,
but a sufficient number of centers would be needed to
have adequate statistical power.
Segregation of HCV-Positive Individuals Within
Dialysis Units
The KDIGO HCV in CKD guideline recommended not
using dedicated dialysis machines for HD patients with
HCV and suggested not isolating HD patients with
HCV.14 Indeed, although there have been no high-
quality randomized trials, there is ample evidence
that the transmission of HCV, whose infectivity is
much lower than that of HBV, can be avoided if hy-
gienic precautions are correctly followed, and isolation
practices may entail the risk of reducing the emphasis
on optimal hygienic practices.14 Thailand was the only
country/region to report following these
recommendations.
Thailand Hemodialysis Clinical Practice Recommen-
dation 2014 does not recommend using dedicated
dialysis machines for patients with blood-borne in-
fections and suggests isolating only those HD patients
who have HBV. It is notable that there has been no
outbreak of HBV or HCV infections in the renal units in
Thailand in the past 5 years. The remaining regions felt
that stigmatization of HCV-positive patients is not a
major problem, and in areas with high HCV prevalence,
it is necessary to isolate patients. Reported isolation
practices vary by region, with all except Thailand us-
ing designated machines. Participants from Singapore
reported not isolating patients physically. Other re-
gions isolate patients within the same room (Hong
Kong, Taiwan, Japan, Malaysia) or within the same
room behind a glass wall or curtains (China, Korea).
Management of CKD Patients With HCV Before
and After Kidney Transplantation
Transplantation Waiting Time and HCV Treatment
Among participating regions, the waiting time for
deceased-donor kidney transplantation is more than 5Kidney International Reports (2020) 5, 1129–1138
PK-T Li et al.: KDIGO HCV Guideline Implementation Asia Summit MEETING REPORTyears, and therefore patients with HCV are likely to be
treated with DAAs as indicated before transplantation.
In nearly all participating regions, in living-donor sit-
uations, anti-HCV treatment is not necessarily done
prior to transplant, so patient preferences become more
important. However, in Taiwan, hepatologists support
HCV treatment as soon as possible in living-donor sit-
uations because it reduces the potential drug–drug
interactions with post-transplant immunosuppressive
regimens.
Anti–HCV-Positive Kidney Donors
Because the prevalence of HCV is low in many Asian
countries, anti–HCV-positive kidney donors are
generally uncommon. Thailand is the only region
where HCV-positive organs can be transplanted into
uninfected recipients if deemed acceptable by re-
cipients. In South Korea, Taiwan, and Hong Kong,
kidneys from anti–HCV-positive donors are accepted
for transplantation into HCV-positive recipients. In
Japan, if deceased donors are HCV RNA–positive, HCV
genotype is tested, and transplantation may be done if
the recipient is HCV RNA–positive and has the same
HCV genotype. In Malaysia, anti–HCV-positive donors
are currently not permitted based upon Ministry of
Health guidelines, but these guidelines will be
reviewed in the near future. In mainland China, there is
no formal policy on this issue.
Assessment of Liver Cirrhosis in Kidney Transplant
Candidates
Meeting participants indicated that transient elastog-
raphy is commonly used to assess extent of liver
fibrosis. Liver biopsy is generally not performed unless
non-invasive assessments are inconclusive or uncer-
tain. However, in regions where patients with
compensated cirrhosis cannot be a candidate for kidney
transplantation, liver biopsy may be needed to confirm
a diagnosis.
Diagnosis and Management of Kidney Diseases
Associated With HCV Infection
Kidney Biopsy and Cryoglobulin Testing
All participants agreed that kidney biopsy is necessary
for assessing histological activity of HCV-related
glomerulonephritis. In Thailand, not all nephrologists
perform biopsies, and availability of renal pathologists
is a barrier to assessing histological activity. In main-
land China and Japan, nephrologists, in addition to
renal pathologists, are involved in pathological inter-
pretation. In Korea, there are generally no limitations
on access to or interpretation of kidney biopsies.
For patients suspected to have HCV-related glomer-
ulonephritis, cryoglobulin testing is still performed in
most participating regions in Asia. However, false
negatives are problematic, and results are not alwaysKidney International Reports (2020) 5, 1129–1138used in treatment decisions. Evidence is needed to
clarify the role of cryoglobulin testing for managing
HCV-related glomerulonephritis.
Treatment
Participants agreed with current KDIGO HCV in CKD
guideline recommendations that patients with severe
cryoglobulinemia or severe glomerular disease induced
by HCV should be treated with immunosuppressive
agents with or without plasma exchange in addition to
DAA therapies.14 Although rituximab is the preferred
immunosuppressive agent, it may not be reimbursed in
some countries, and further research is needed on how
to stratify or identify patients for early rituximab
therapy.
In all cases, careful monitoring of HCV RNA levels,
changes in kidney function, evolution of proteinuria,
and side effects from antiviral therapy is necessary.
Approaches for Improving Guideline Adherence
Awareness
Approaches that could increase regional awareness of
the KDIGO HCV in CKD guideline include incorpo-
rating its recommendations within local guidelines,
developing shortened or simplified guideline sum-
maries, translating the guideline into languages beyond
English and Chinese, and developing an app for more
widespread accessibility. Participants also felt that the
algorithms for HCV testing and management could be
simplified, which could in turn increase the under-
standing of the steps needed to achieve individual cure
and monitoring of HCV. Broadening screening recom-
mendations could increase awareness of HCV and ac-
cess to testing and treatment. To this end, in early
2020, the US Preventive Services Task Force expanded
HCV screening recommendations to one-time, universal
screening for all adults aged 18 to 79 years.33
Microelimination strategies23,32,34,35 in specific re-
gions or within dialysis units could serve as models to
demonstrate that elimination is possible, providing
more evidentiary support for adhering to the KDIGO
HCV in CKD guideline and realizing the goal by the
World Health Organization to eliminate HCV as a
public health problem by 2030.36
DAA Availability and Cost
Having more widely available licensed generic DAA
regimens would increase the numbers of patients who
can be treated. WHO has promoted driving increased
access to DAA-based treatment through steep price
reductions which have occurred due largely to
increased competition, especially from generic manu-
facturers.37 A voluntary license is an agreement be-
tween an originator manufacturer and a generic
manufacturer that allows the production and sale of a1135
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terms. It has been reported that voluntary licensing
initiatives appeared to substantially improve HCV
treatment uptake in eligible countries.38 This evidence
supports the expansion of licensing strategies to
include more countries and more treatments. However,
the number of countries and regions in Southeast Asia
with available generic DAA regimens seems unlikely to
change in the near future. More interventions through
multiple parties, including governments, are required
to speed up the expanded access to generic DAA reg-
imens in the region. Reducing patient copays would
also make regimens more accessible to patients.
KDIGO’s Role in Assisting Guideline
Implementation
Cost and reimbursement policies are among the key
barriers to implementing the HCV in CKD guideline.
KDIGO could consider analyzing and reporting health
economics related to HCV infection and its treatment in
CKD. Such cost-effectiveness data are important for
developing health policies and could help bridge the
gap between guideline recommendations and imple-
mentation. Incentivizing payer funding for DAA
treatments may result in lower healthcare costs in the
long run. General formulas for calculating the incre-
mental cost-effectiveness ratio could be developed, and
calculations could be individualized based on actual
costs in specific regions or countries. KDIGO also may
consider developing web-based education and training
materials, such as podcasts, regionally relevant man-
agement toolkits, and decision-support aids to assist
clinicians in providing structured HCV care. KDIGO is
ready to partner with local professional organizations
or national nephrology societies on efforts toward
guideline education, training, and implementation.
Preventing HCV transmission within HD units is a
reachable goal if auditing and appropriate education of
staff are implemented and prioritized by national and
local leaders.
CONCLUSIONS
Limited availability and high costs of DAA regimens
are major barriers to HCV treatment in CKD pop-
ulations in many Asian countries. In regions where
DAAs are more available and affordable, limited patient
awareness of HCV status and treatment options is a
common barrier. Infection control practices in dialysis
units vary among regions, with most still either
physically isolating patients with HCV or using
designated dialysis machines. The strategy of micro-
elimination of HCV from specific CKD populations,
such as dialysis patients, may be an achievable goal in
some countries and regions. Using the HCV in CKD1136KDIGO guideline as a tool to aid in moving toward
successful microelimination could lead to further
awareness and uptake of the guideline in the CKD
population.DISCLOSURE
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